Imago BioSciences announces $40M Series B financing led by Omega Funds

On 21 March, Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, announced a $40 million Series B financing led by Omega Funds, a GJE client and leading international investment firm that creates and invests in life sciences companies.

Proceeds from the financing will be used to advance the research and clinical development program of therapeutics for myelofibrosis and other myeloid neoplasms.

Gill Jennings & Every LLP provided advice on the IP-related aspects of the transaction. The GJE team was led by partner, Fiona Stevens, assisted by Esmé Swindells.

GJE has a dedicated investor group, focused on understanding the needs of today’s investors and developing services to meet those needs. See here for more information. Fiona Stevens has taken part in developing the firm’s unique IP services, ConsultIPIncluded within the ConsultIP products is the Due Diligence Audit to support investors. It assesses the IP owned by a target company to ensure it covers their innovation, and evaluates the execution of its business plan, to minimise IP-risk and maximise return on investment.